当前位置:首页 > 报告详情

McKesson-2026-JPM.pdf

上传人: 明**** 编号:1069762 2026-01-17 27页 3.34MB

1、 2026 McKesson Corporation.All rights reserved.1McKesson CorporationJ.P.Morgan Healthcare ConferenceJanuary 13,2026Brian TylerChief Executive Officer 2026 McKesson Corporation.All rights reserved.2Cautionary StatementsCautionary StatementsThis presentation contains forward-looking statements within

2、the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.Forward-looking statements may be identified by their use of terminology such as“believes,”“expects,”“anticipates,”“may,”“will,”“should,”“seeks,”“approximately,”“intends,”“projects,”“plans

3、,”“estimates,”“targets,”or the negative of these words or other comparable terminology.Any discussion of our intent to separate our Medical-Surgical Solutions segment into an independent company and to sell our business in Norway,other anticipated or completed transactions,including the anticipated

4、closings thereof,or synergies expected therefrom,litigation outcomes,financial outlook,guidance,trends,strategy,plans,assumptions,expectations,commitments,and intentions may also include forward-looking statements.Readers should not place undue reliance on forward-looking statements,such as financia

5、l performance forecasts,which speak only as of the date they are first made.Except to the extent required by law,we undertake no obligation to update or revise our forward-looking statements.Forward-looking statements involve risks and uncertainties that could cause actual results to differ material

6、ly from those projected,anticipated,or implied.Although it is not possible to predict or identify all such risks and uncertainties,we encourage investors to read the risk factors described in our publicly available filings with the Securities and Exchange Commission and news releases.These risk fact

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **公司战略与目标**:McKesson致力于推进全民健康成果,核心战略包括有机增长、运营杠杆和资本配置,目标实现13%-16%的调整后每股收益(EPS)长期增长。 2. **财务表现**:2026财年调整后运营利润预期为63亿-65亿美元,调整后EPS为38.35-38.85美元,自由现金流44亿-48亿美元,ROIC约30%,杠杆率1.3x。 3. **业务转型**:通过剥离挪威业务及优化投资组合,聚焦肿瘤与多专科平台、处方技术解决方案(RxTS)及生物制药服务,其中肿瘤市场预计2025-2029年药物支出增长显著。 4. **风险提示**:包含前瞻性声明,涉及法律纠纷、网络安全、医疗政策变化等风险,实际结果可能与预期存在重大差异。 5. **非GAAP指标**:公司使用调整后利润等非GAAP指标补充分析,需参考附录及SEC文件进行GAAP调整。
麦克森前景如何? 增长目标是什么? 风险有哪些?
客服
商务合作
小程序
服务号
折叠